Recent News from the CGRP Forum

Meta analysis of anti-CGRP therapy underlines efficacy and safety

CGRP monoclonal antibody therapy significantly reduces monthly migraine days and migraine-specific medication consumption from baseline (weighted mean difference [WMD] = - 1.52; 95%CI - 1.92 to - 1.11, p < 0.001; and - 1.45; 95%CI, - 2.17 to - 0.72, p< 0.001, respectively).

Read the full report here »

Is CGRP a novel target for cardiovascular treatment?

Growing interest in the highly potent vasoactive peptide, CGRP, as a novel treatment for cardiovascular disease is addressed in a recent review of CGRP research in hypertension, ischaemia and heart failure.

Read the full report here »

Cryo-EM sheds new light on CGRP receptor function

Cryo-electron microscopy has been used to explore the structure of the active human CGRP receptor in complex with CGRP and the Gs-protein heterotrimer, and to provide new insights into the control of G-protein-coupled receptor function.

Read the full report here »

Pivotal studies published for erenumab and galcanezumab

Efficacy and tolerability data from the Liberty study of erenumab in patients who had previously failed two-to four preventive therapies, and 100% response data for galcanezumab in the EVOLVE-1 and EVOLVE-2 studies have been published.

Read the full report here »

Should children and adolescents with migraine have anti-CGRP therapy?

Children and adolescents may be considered for anti-CGRP therapy in appropriate cases, with close follow-up and attention to patients’ age, pubertal state, medical comorbidities and other characteristics. These are the conclusions of members of the Pediatric and Adolescent Headache special interest group of the American Headache Society (AHS), in the current absence of clinical trial data in this age group.

Read the full report here »